Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
JAMA
    March 2024
  1. KO D, Pascual-Leone A, Shah SJ
    Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.
    JAMA. 2024 Mar 15. doi: 10.1001/jama.2024.2991.
    >> Share

  2. HARRIS E
    Biomarker Changes Can Begin 18 Years Before Alzheimer Disease Diagnosis.
    JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1568.
    >> Share

    February 2024
  3. HARRIS E
    Aducanumab Combined With Focused Brain Ultrasound More Effective.
    JAMA. 2024;331:466-467.
    >> Share

  4. HARRIS E
    Commercial Blood Test May Identify Alzheimer Disease Brain Pathology.
    JAMA. 2024 Feb 7. doi: 10.1001/jama.2024.0175.
    >> Share

    December 2023
  5. POMARA N, Imbimbo BP
    Use of Donanemab in Early Symptomatic Alzheimer Disease.
    JAMA. 2023;330:2304.
    >> Share

  6. EVANS CD, Sims JR
    Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
    JAMA. 2023;330:2304-2305.
    >> Share

    November 2023
  7. RAFII MS, Fortea J
    Down Syndrome in a New Era for Alzheimer Disease.
    JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22924.
    >> Share

    September 2023
  8. RUBIN R
    Who Should-and Can-Get Lecanemab, the New Alzheimer Disease Drug?
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.14443.
    >> Share

  9. ODOUARD IC, Socal MP, Anderson GF
    Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.17131.
    >> Share

  10. RUBIN R
    Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?
    JAMA. 2023 Sep 13. doi: 10.1001/jama.2023.17685.
    >> Share

    August 2023
  11. HARRIS E
    Study: Identifying Lewy Body Disease Before Symptoms.
    JAMA. 2023;330:686.
    >> Share

    July 2023
  12. HARRIS E
    MIND Diet No Better Than Control for Adults at Risk of Dementia.
    JAMA. 2023 Jul 26. doi: 10.1001/jama.2023.13134.
    >> Share

  13. HARRIS E
    Alzheimer Drug Lecanemab Gains Traditional FDA Approval.
    JAMA. 2023 Jul 19. doi: 10.1001/jama.2023.12548.
    >> Share

  14. SIMS JR, Zimmer JA, Evans CD, Lu M, et al
    Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    JAMA. 2023 Jul 17:e2313239. doi: 10.1001/jama.2023.13239.
    >> Share

  15. ROSENTHAL MB
    Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11702.
    >> Share

  16. MANLY JJ, Deters KD
    Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11704.
    >> Share

  17. RABINOVICI GD, La Joie R
    Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11703.
    >> Share

  18. WIDERA EW, Brangman SA, Chin NA
    Ushering in a New Era of Alzheimer Disease Therapy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11701.
    >> Share

  19. HARRIS E
    More Lean Muscle Might Reduce Alzheimer Disease Risk.
    JAMA. 2023 Jul 12. doi: 10.1001/jama.2023.12544.
    >> Share

    June 2023
  20. HARRIS E
    CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    JAMA. 2023 Jun 14. doi: 10.1001/jama.2023.10400.
    >> Share

  21. HARRIS E
    Brain Cell Biomarker for Preclinical Alzheimer Disease Identified.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9928.
    >> Share

    May 2023
  22. HARRIS E
    FDA Greenlights First Drug for Agitation Related to Alzheimer Disease.
    JAMA. 2023 May 24. doi: 10.1001/jama.2023.9153.
    >> Share

  23. MARCUS R
    New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines-Highlights From the 2023 American Academy of Neurology Conference.
    JAMA. 2023 May 10. doi: 10.1001/jama.2023.4389.
    >> Share

    March 2023
  24. HARRIS E
    Blood Biomarker Helps Distinguish Vascular Dementia.
    JAMA. 2023;329:969.
    >> Share

    February 2023
  25. HARRIS E
    Healthful Lifestyle May Slow Memory Loss, Even for APOE Gene Carriers.
    JAMA. 2023;329:622.
    >> Share

  26. LE GUEN Y, Raulin AC, Logue MW, Sherva R, et al
    Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease.
    JAMA. 2023;329:551-560.
    >> Share

    January 2023
  27. LARKIN HD
    Lecanemab Gains FDA Approval for Early Alzheimer Disease.
    JAMA. 2023 Jan 18. doi: 10.1001/jama.2022.24490.
    >> Share

  28. LARKIN H
    Noninvasive Sensory Stimulation With Light and Sound Tested in Alzheimer Disease.
    JAMA. 2023;329:114.
    >> Share

    September 2022
  29. HARRIS E
    Large Autopsy Study Estimates Prevalence of "LATE" Neuropathologic Change.
    JAMA. 2022;328:815-816.
    >> Share

    August 2022
  30. RUBIN R
    Much Anticipated Alzheimer Disease Prevention Trial Finds No Clinical Benefit From Drug Targeting Amyloid; Highlights Need to Consider Other Approaches.
    JAMA. 2022 Aug 17. pii: 2795592. doi: 10.1001/jama.2022.11490.
    >> Share

  31. DEPEW R
    To My Husband With Alzheimer Disease.
    JAMA. 2022;328:587.
    >> Share

  32. SLOMSKI A
    Anti-Tau Antibody Semorinemab Fails to Slow Alzheimer Disease.
    JAMA. 2022;328:415.
    >> Share

    July 2022
  33. SURAN M
    Some Antioxidants May Mitigate the Risk of Dementias.
    JAMA. 2022;328:321.
    >> Share

    June 2022
  34. RUBIN R
    New Test to Help Diagnose Alzheimer Disease.
    JAMA. 2022;327:2281.
    >> Share

    May 2022
  35. LARKIN HD
    First Donepezil Transdermal Patch Approved for Alzheimer Disease.
    JAMA. 2022;327:1642.
    >> Share

    December 2021
  36. SLOMSKI A
    Methylphenidate Treats Apathy in Alzheimer Disease.
    JAMA. 2021;326:2120.
    >> Share

    October 2021
  37. EMANUEL EJ
    A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    JAMA. 2021;326:1367-1368.
    >> Share

    September 2021
  38. ANDERSON TS, Ayanian JZ, Souza J, Landon BE, et al
    Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
    JAMA. 2021 Sep 9. pii: 2784225. doi: 10.1001/jama.2021.15286.
    >> Share

    August 2021
  39. RUBIN R
    CMS Considers Controversial Alzheimer Drug Coverage.
    JAMA. 2021;326:690.
    >> Share

    July 2021
  40. RUBIN R
    Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    JAMA. 2021 Jul 21. pii: 2782427. doi: 10.1001/jama.2021.11558.
    >> Share

  41. SCHULMAN KA, Greicius MD, Richman B
    Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    JAMA. 2021 Jul 19. pii: 2782333. doi: 10.1001/jama.2021.11768.
    >> Share

    June 2021
  42. CHEN MH, Yang FC, Liang CS
    APOE Allele Testing and Alzheimer Disease.
    JAMA. 2021;325:2210-2211.
    >> Share

  43. CHOUDHURY P, Ramanan VK, Boeve BF
    APOE Allele Testing and Alzheimer Disease-Reply.
    JAMA. 2021;325:2211.
    >> Share

    April 2021
  44. RUBIN R
    Neurologist Faces His Alzheimer Diagnosis Determined to Lessen Stigma Surrounding the Disease.
    JAMA. 2021 Apr 28. pii: 2779452. doi: 10.1001/jama.2021.5333.
    >> Share

    March 2021
  45. ALEXANDER GC, Emerson S, Kesselheim AS
    Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    JAMA. 2021 Mar 30. pii: 2778191. doi: 10.1001/jama.2021.3854.
    >> Share

    January 2021
  46. CHOUDHURY P, Ramanan VK, Boeve BF
    APOE varepsilon4 Allele Testing and Risk of Alzheimer Disease.
    JAMA. 2021 Jan 14. pii: 2775399. doi: 10.1001/jama.2020.15085.
    >> Share

    November 2020
  47. MADDOX M
    Alzheimer Aubade.
    JAMA. 2020;324:2108.
    >> Share

    October 2020
  48. TSOU AY, Bulova P, Capone G, Chicoine B, et al
    Medical Care of Adults With Down Syndrome: A Clinical Guideline.
    JAMA. 2020;324:1543-1556.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016